Companies /Healthcare

X4 Pharmaceuticals Inc

NASDAQ: XFOR Biotechnology

$2.59

▼ $0.05 (−1.89%) today

Markets closed · 1:07am ET

XFOR at a Glance

Valuation

Market cap: $256.8M
P/E ratio: 129.5

Profitability

Revenue (TTM): $15.8M
EPS (TTM): $0.02

Price

52-week range: $2 – $5
Street target: $11.60

Earnings

Next report: Nov 4, 2026

Headquartered in Boston, MA Fiscal year ends December NASDAQ: XFOR x4pharma.com

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a biopharmaceutical company based in Boston, Massachusetts, dedicated to creating treatments for rare diseases. Its flagship project, mavorixafor, is a promising drug in advanced clinical trials aimed at addressing a range of conditions, including a syndrome characterized by warts, immune deficiencies, and infections. Additionally, X4 Pharmaceuticals is exploring potential therapies for brain cancers and other disorders linked to the CXCR4 receptor. The company collaborates with Abbisko Therapeutics for oncology treatments, showcasing its commitment to innovative healthcare solutions.

XFOR Coverage

11:15am ET

Investing

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts. All three names carry verified…

IMRX TNGX XFOR

Joel South

Frequently Asked Questions

What does X4 Pharmaceuticals do?

X4 Pharmaceuticals Inc is a biopharmaceutical company based in Boston, Massachusetts, dedicated to creating treatments for rare diseases.

What is the XFOR stock price target?

The Wall Street consensus 12-month price target for XFOR is $11.60.